Marshall Edwards, Inc. Commences Renal Cancer Human Trial of Phenoxodiol in Combination Therapy
March 08 2004 - 9:57AM
PR Newswire (US)
Marshall Edwards, Inc. Commences Renal Cancer Human Trial of
Phenoxodiol in Combination Therapy WASHINGTON, and SYDNEY,
Australia, March 8 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc.
(LONDON: MSH) has commenced a study that will test the ability of
its investigational anti-cancer drug, phenoxodiol, to enhance the
effect of platinum drugs in patients with solid cancers,
particularly late-stage renal carcinoma (cancer of the kidney). The
study is being conducted at St George Hospital, Sydney, Australia.
The Principal Investigator is Paul de Souza MD. The patients in the
study will have late-stage cancers that are no longer responding to
standard chemotherapies. These chemotherapies include platinum
drugs such as cisplatin and carboplatin, that commonly are used as
first-line therapies for a wide range of cancers because of their
potency. Most patients eventually become resistant to such drugs so
overcoming that resistance has become an urgent medical need. In
the laboratory, phenoxodiol has shown a potent ability in cancer
cells to reverse chemo-resistance to drugs such as cisplatin and
carboplatin. The basis of this reversal is thought to be the
ability of phenoxodiol to remove blocking proteins such as XIAP
(X-linked Inhibitor of Apoptosis Protein), which are over-expressed
in cancer cells. In this study, phenoxodiol will be administered in
the oral dosage form. Patients will take capsules of phenoxodiol,
in one of four dose strata, three times a day, for treatment cycles
of 12 weeks. Patients will also either receive cisplatin or
carboplatin once weekly at a fixed dose. One of the main objectives
of the study is to determine the appropriate dose level of
phenoxodiol for renal cancer. Studies have shown that phenoxodiol
is likely to be more effective at lower, rather than higher doses
for a wide range of applications. Dr. Graham Kelly, Executive
Chairman of Marshall Edwards, Inc., said, "Phenoxodiol is an
exciting prospect for the reversal of chemo-resistance in
late-stage cancers where patients have no therapeutic options
remaining. This study is one of a number where we are testing that
proposition. "Preliminary studies to date indicate that phenoxodiol
may enhance ability of drugs such as platinums to kill cancer
cells, without impacting normal cells. This study hopes to confirm
that. "Another important objective is to confirm the therapeutic
benefit of phenoxodiol combinational therapy in patients
particularly those with late- stage renal carcinoma (cancerof the
kidney). Based on our clinical experience to date, we have good
reason to believe that phenoxodiol has considerable potential in
this deadly form of cancer," Kelly added. Marshall Edwards, Inc. is
pursuing a dual strategy of developing phenoxodiol for the
treatment of both early-stage cancers and late-stage cancers. The
strategy in early-stage cancers of using phenoxodiol as a
monotherapy is intended to result in the killing of cancer cells
before they have had a chance to develop the pro-survival
techniques, involving apoptosis blocking proteins, that
characterize many late-stage cancers. The strategy being employed
for the late-stage cancers is to use phenoxodiol in combination
with standard drugs such as paclitaxel and cisplatin. Phenoxodiol
was developed by Novogen Limited (NASDAQ:NVGN)(ASX:NRT) and
licensed to Marshall Edwards, Inc. It is an investigational
anti-cancer drug that has yet to receive marketing approval by
regulatory authorities. Statements included in this press release
that are not historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. You should be aware that
our actual results could differ materially from those contained in
the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any productsto gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: Australia: Graham Kelly of Marshall Edwards, Inc.,
+011-61 2 9878 0088; or in the U.S.: David Sheon, +1-202-518-6384,
for Marshall Edwards, Inc.
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024